Lisa Delfini

Companies

• Trevi Therapeutics, Inc.Chief financial officer Aug 9, 2021 to Jan 12, 2026¹

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• TTTrevi Therapeutics, Inc. TRVI64,660 shares²$785.0K at $12.14Jan 8, 2025

As of each latest filing. The line shows shares held over time.

Recent filings

• Jan 8, 2025Exercised options 5,000 shares at $0.51 of Trevi Therapeutics, Inc.²
• Jan 7, 2025Exercised options 1,000 shares at $0.51 of Trevi Therapeutics, Inc.²
• May 22, 2024Sold 4,350 shares at $2.64 of Trevi Therapeutics, Inc.³
• May 22, 2024Exercised options 16,043 shares at $0.51 of Trevi Therapeutics, Inc.³
• Oct 11, 2023Sold 785 shares at $2.02 of Trevi Therapeutics, Inc.⁴
• Oct 11, 2023Exercised options 2,292 shares at $0.51 of Trevi Therapeutics, Inc.⁴
• Sep 11, 2023Sold 711 shares at $2.20 of Trevi Therapeutics, Inc.⁵
• Sep 11, 2023Exercised options 2,291 shares at $0.51 of Trevi Therapeutics, Inc.⁵
• Aug 11, 2023Sold 682 shares at $2.36 of Trevi Therapeutics, Inc.⁶
• Aug 11, 2023Exercised options 2,292 shares at $0.51 of Trevi Therapeutics, Inc.⁶
• Jul 11, 2023Sold 687 shares at $2.34 of Trevi Therapeutics, Inc.⁷
• Jul 11, 2023Exercised options 2,292 shares at $0.51 of Trevi Therapeutics, Inc.⁷
• Jun 12, 2023Sold 610 shares at $2.64 of Trevi Therapeutics, Inc.⁸
• Jun 12, 2023Exercised options 2,291 shares at $0.51 of Trevi Therapeutics, Inc.⁸
• May 11, 2023Sold 562 shares at $2.89 of Trevi Therapeutics, Inc.⁹
• May 11, 2023Exercised options 2,291 shares at $0.51 of Trevi Therapeutics, Inc.⁹
• Apr 11, 2023Sold 840 shares at $1.84 of Trevi Therapeutics, Inc.¹⁰
• Apr 11, 2023Exercised options 2,292 shares at $0.51 of Trevi Therapeutics, Inc.¹⁰
• Mar 13, 2023Sold 892 shares at $1.75 of Trevi Therapeutics, Inc.¹¹
• Mar 13, 2023Exercised options 2,291 shares at $0.51 of Trevi Therapeutics, Inc.¹¹
• Feb 13, 2023Sold 8,474 shares at $2.45 of Trevi Therapeutics, Inc.¹²
• Feb 13, 2023Exercised options 27,500 shares at $0.51 of Trevi Therapeutics, Inc.¹²